- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00440440
Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes
August 6, 2015 updated by: Diabetes Center of the Southwest
Effect of Androgel on Total and Regional Adipose Tissue and Lean Body Mass in Type 2 Diabetic Patients With Hypogonadism
The purpose of the study is to find out the effect of replacing testosterone in the form of a gel (Androgel®) on the amount of fat mass in males with low testosterone and diabetes.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Hypogonadism is associated with increase in fat mass, decrease in muscle mass, accelerated bone loss, decreased libido and effects on mood.
Androgen replacement in this context is clearly beneficial, and numerous studies have demonstrated improvements in bone and muscle mass, reductions in body fat and improvement in insulin sensitivity, libido and mood following treatment.
Testosterone replacement leads to a dose-dependent decrease in adipose tissue and increase in muscle mass and strength.
The principal focus of the proposed research is to evaluate the effect of androgel on lean body mass and regional adipose tissue mass (including hepatic and visceral fat) in type 2 diabetic patients with hypogonadism, a population that is likely to benefit from a reduction in adipose tissue and an increase in muscle mass.
Study Type
Interventional
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Midland, Texas, United States, 79707
- Diabetes Center of the Southwest
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males with age 35-75 years inclusive.
- Evidence of hypogonadism: Hypogonadism will be defined as low total testosterone (<300 ng/dL) and low calculated free testosterone (below 6.5ng/dL; calculated using testosterone and SHBG). Testosterone levels will be measured between 8 and 10 am. Subjects who have normal total but low free testosterone levels (or vice versa) will be asked to come again after one week to have their testosterone levels re-measured. They will be included in the study in their free and total testosterone levels are low on re-measurement.
- Type 2 diabetes
- Hemoglobin A1c <8.0 %
- Subjects on medications for diabetes will be allowed as long as they are on stable doses of these compounds for at least 6 weeks. The dose of thiazolidinediones will have to be stable for 3 months prior to the study. The dosage of diabetic medications will not be changed during the study.
Exclusion Criteria:
- Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks
- Hepatic disease (transaminase > 3 times normal)
- Renal impairment (serum creatinine > 1.5)
- Chronic steroid therapy
- Use of testosterone or other androgens (such as DHEA) in the last 3 months
- Panhypopituitarism
- HIV or hepatitis C
- Subjects will be excluded from the study for history of prostate or breast cancer, gonadal endocrine disorders
- Current or recent history of major psychiatric illness, significant uncontrolled systemic illness
- Sleep apnea
- History of alcoholism or substance abuse within the past year
- History of taking other drugs that might interfere with the results of the study (ie, Lupron, finasteride, spironolactone, cimetidine, antiandrogens, estrogens, p450 enzyme inducers, barbiturates)
- Abnormal prostate evidenced by prostatic symptoms, prostatic masses or induration on rectal examination, elevated levels of prostate specific antigen (>4 ng/mL; subjects with PSA levels between 2.5-4 ng/mL will be permitted if prostate biopsy is negative) or positive biopsy, a urine flow rate of less than 12 mL/s, or an International Prostate Symptom Score greater than 19
- Hematocrit greater than 50%
- Body weight >300 lbs (this is the maximum weight that can be accommodated on DEXA or MRI machines.
- The subject has systolic blood pressure >170mmHg or diastolic blood pressure >100 mmHg while on or off anti-hypertensive treatment.
- Generalized skin disease that could affect the absorption of testosterone gel (ie, psoriasis);
- Morning prolactin level greater than 40 mg/mL
- Subjects with serum fasting triglyceride concentration > 500 mg/dL at screening or with history of hypertriglyceridemia-induced pancreatitis.
- Participation in any other concurrent clinical trial
- Any other life-threatening, non-cardiac disease
- Use of an investigational agent or therapeutic regimen within 30 days or 5 half-lives (which ever is longer) preceding the first dose of study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
testosterone gel
|
Testosterone gel to be applied daily, starting does 5g.
Other Names:
|
Placebo Comparator: 2
placebo gel
|
placebo gel apply daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean absolute change in visceral adipose tissue mass in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy.
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Study the effect in type 2 diabetic subjects with hypogonadism after 6 months of androgel therapy on:
Time Frame: 6 months
|
6 months
|
Mean absolute change in hepatic fat measured by NMR spectroscopy.
Time Frame: 6 months
|
6 months
|
Mean absolute change in total and regional adipose tissue mass measured by DEXA
Time Frame: 6 months
|
6 months
|
Mean absolute change in total and regional lean body mass measured by DEXA.
Time Frame: 6 months
|
6 months
|
Mean absolute change in total body and regional (arm, leg, ribs) BMC and BMD
Time Frame: 6 months
|
6 months
|
Mean absolute change in hip BMC and BMD (mean of two hips)
Time Frame: 6 months
|
6 months
|
Mean absolute change in spine BMC and lumbar spine (L1-L4) BMD
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sandeep Dhindsa, MBBS, Diabetes Center of the Southwest
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Anticipated)
November 1, 2011
Study Completion (Anticipated)
July 1, 2012
Study Registration Dates
First Submitted
February 23, 2007
First Submitted That Met QC Criteria
February 26, 2007
First Posted (Estimate)
February 27, 2007
Study Record Updates
Last Update Posted (Estimate)
August 10, 2015
Last Update Submitted That Met QC Criteria
August 6, 2015
Last Verified
August 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GR-940
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on Testosterone gel
-
University of WashingtonNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedHealthyUnited States
-
VA Office of Research and DevelopmentRecruiting
-
BioSante PharmaceuticalsCompletedHypoactive Sexual Desire DisorderUnited States, Canada
-
Biolab Sanus FarmaceuticaWithdrawnPost-menopausal Period
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Acerus Pharmaceuticals CorporationCompletedFemale Sexual DysfunctionUnited States
-
University of WashingtonNational Institute on Aging (NIA); Solvay PharmaceuticalsCompletedMild Cognitive Impairment | Alzheimer's DiseaseUnited States
-
University of PennsylvaniaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
McGuire Research InstituteSolvay PharmaceuticalsCompletedMetabolic Syndrome | HypogonadismUnited States
-
University Medical Center GroningenActive, not recruiting